Skip to main content
SpringerLink
Log in

ASH 2018—aggressive lymphoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

At the American Society of Hematology Meeting (ASH) 2018 promising data were presented reflecting the impressing advances of clinical research in aggressive lymphoma. Besides promising and partially practice-changing therapies in first-line treatment, there was a focus on Chimeric Antigen Receptor T Cell (CART) therapy for patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): longer follow-up, real world data and new developments were reported. A bit overshadowed by CART therapy hype promising data for adding venetoclax to chemoimmuntherapy, bispecific antibodies, antibody drug conjugates and new monoclonal antibodies were presented. Important data to detect patients at high risk for R/CHOP (Rituximab/Cyclophospamide, Doxorubicin, Vincristine, Prednisone) failure and to detect possible targets for this high-risk subgroup were shown. The focus of phase III studies in the future should be on this high-risk population as the next phase III trial—the PHOENIX study adding ibrutinib to R/CHOP in non GCB DLBCL—failed to improve standard first-line therapy with R/CHOP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rosenwald A, et al. Prognostic Significance of MYC Single, Double, Triple Hit and MYC-Translocation Partner Status in Diffuse Large B‑Cell Lymphoma—a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC). Blood. 2018;132:344.

    Google Scholar 

  2. Staiger AM, et al. A new Stromal signature applicable to formalin-fixed paraffin-embedded tissues identifies patients at risk in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2018;132:343.

    Article  Google Scholar 

  3. Poeschel V, et al. Excellent outcome of young patients (18–60 years) with favourable-prognosis diffuse large B‑cell Lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of Rituximab: results of the 592 patients of the flyer trial of the Dshnhl/GLA. Blood. 2018;132:781.

    Google Scholar 

  4. Younes A, et al. A global, randomized, placebo-controlled, phase 3 study of Ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B‑cell-like (GCB) diffuse large B‑cell Lymphoma (DLBCL). Blood. 2018;132:784.

    Google Scholar 

  5. Davies A, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B‑cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):P649–P62.

    Article  Google Scholar 

  6. Leonard JP, et al. Randomized phase II study of R‑CHOP with or without Bortezomib in previously untreated patients with non-germinal center B‑cell-like diffuse large B‑cell Lymphoma. J Clin Oncol. 2017;35(31):3538–46.

    Article  CAS  Google Scholar 

  7. Vitolo U, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B‑cell lymphoma. J Clin Oncol. 2017;35(31):3529–37.

    Article  CAS  Google Scholar 

  8. Witzig TE, et al. Adjuvant everolimus in high-risk diffuse large B‑cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29(3):707–14.

    Article  CAS  Google Scholar 

  9. Crump M, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B‑cell Lymphoma. J Clin Oncol. 2016;34(21):2484–92.

    Article  CAS  Google Scholar 

  10. Franck Morschhauser, et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B‑cell Lymphoma (DLBCL): first safety, efficacy and Biomarker analyses from the phase II CAVALLI study. Blood. 2018;132:782.

    Google Scholar 

  11. Chamuleau MED, et al. Successful treatment of MYC rearrangement positive large B cell lymphoma patients with R‑CHOP21 plus lenalidomide: results of a multicenter phase II HOVON trial. Blood. 2018;132:786.

    Google Scholar 

  12. Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B‑cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.

    Article  CAS  Google Scholar 

  13. Nastoupil LJ, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T‑cell therapy for relapsed/refractory large B‑cell lymphoma: real world experience. Blood. 2018;132:91.

    Article  Google Scholar 

  14. Neelapu SS, et al. 2‑year follow-up and high-risk subset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Blood. 2018;132:2967.

    Google Scholar 

  15. Lung-Ji Chang, et al. Phase I/II trial of multi-target chimeric antigen receptor modified T cells (4SCAR2.0) against relapsed or refractory lymphomas. Blood. 2018;132:225.

    Google Scholar 

  16. Park JH, et al. A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including richter’s transformation. Blood. 2018;132:224.

    Google Scholar 

  17. Henia Dar, et al. Preclinical development of CTX120, an allogeneic CAR-T cell targeting Bcma. Blood. 2018;132:1921.

    Google Scholar 

  18. Chong EA, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T‑cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B‑cell non-Hodgkin lymphomas. Blood. 2018;132:4198.

    Google Scholar 

  19. Hirayama AV, et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B‑cell non-hodgkin Lymphoma. Blood. 2018;132:1680.

    Google Scholar 

  20. Salles GA, et al. Single-arm phase II study of MOR208 combined with Lenalidomide in patients with relapsed or refractory diffuse large B‑cell lymphoma: L‑mind. Blood. 2018;132:227.

    Google Scholar 

  21. Caimi P, et al. Safety and efficacy of Venetoclax combined with rituximab, Ifosfamide, carboplatin and etoposide chemoimmunotherapy (VICER) for treatment of relapsed diffuse large B cell Lymphoma: results from the phase 1 study. Blood. 2018;132:397.

    Google Scholar 

  22. Sehn LH, et al. Polatuzumab Vedotin (Pola) plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B‑cell Lymphoma (DLBCL): updated results of a phase (Ph) Ib/II study. Blood. 2018;132:1683.

    Google Scholar 

  23. Budde LE, et al. Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B‑cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132:399.

    Google Scholar 

  24. Hutchings M, et al. CD20-Tcb (RG6026), a novel “2:1” format T‑cell-engaging Bispecific antibody, induces complete remissions in relapsed/refractory B‑cell non-hodgkin’s lymphoma: preliminary results from a phase I first in human trial. Blood. 2018;132:226.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, Heinrich Collin Str. 30, 1140, Vienna, Austria

    Michael Panny

Authors
  1. Michael Panny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Panny.

Ethics declarations

Conflict of interest

M. Panny declares that he has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panny, M. ASH 2018—aggressive lymphoma. memo 12, 207–211 (2019). https://doi.org/10.1007/s12254-019-0510-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-019-0510-9

Keywords

Search

Navigation